Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Monte Rosa Therapeutics Q4 EPS $(0.58) Misses $(0.33) Estimate; Cash Balance Of $237M Is Expected To Provide Cash Runway Into First Half Of 2026

Author: Benzinga Newsdesk | March 14, 2024 07:12am
Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.33) by 75.76 percent. This is a 7.94 percent increase over losses of $(0.63) per share from the same period last year.

Posted In: GLUE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist